,
,
17 Physiopathologie immunitaire et mode d'action des inhibiteurs des points de contrôle immunitaires ,
Les concepts d'immunothérapie ciblée et de « check points ,
,
, ses ligands et les molécules anti PD1
, Effets indésirables des immunothérapies anti CTLA-4 et anti PD-1
,
,
,
,
,
,
Caractéristiques selon la molécule utilisée et comparaison à la littérature ,
,
,
,
,
Clinical blockade of PD1 and LAG3-potential mechanisms of action, Nat Rev Immunol, vol.15, issue.1, pp.45-56, 2014. ,
Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, vol.439, issue.7077, pp.682-689, 2006. ,
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade, J Clin Invest, vol.125, issue.9, pp.3377-83, 2015. ,
DOI : 10.1172/jci80012
URL : http://www.jci.org/articles/view/80012/files/pdf
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and metaanalysis of anti-CTLA-4 and anti-PD-1 agents trials, Cancer Med, vol.5, issue.7, pp.1481-91, 2016. ,
Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis, Transl Oncol, vol.9, issue.1, pp.32-40, 2016. ,
DOI : 10.1016/j.tranon.2015.11.010
URL : https://doi.org/10.1016/j.tranon.2015.11.010
Efficacité des inhibiteurs du checkpoint immunitaire PD-1/PD-L1 et testing PD-L1 dans les cancers thoraciques, Ann Pathol, vol.37, issue.1, pp.61-78, 2017. ,
DOI : 10.1016/j.annpat.2016.12.009
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation. The Oncologist, vol.13, pp.2-9, 2008. ,
Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.2010, issue.363, pp.711-723, 2010. ,
DOI : 10.1056/nejmoa1003466
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints, Int J Mol Sci, vol.17, issue.12, p.1151, 2016. ,
Pembrolizumab: A Review in Advanced Melanoma, Drugs, vol.76, issue.3, pp.375-86, 2016. ,
DOI : 10.1007/s40265-016-0543-x
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat Rev, vol.45, pp.7-18, 2016. ,
Immunerelated adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer, vol.54, pp.139-187, 2016. ,
DOI : 10.1016/j.ejca.2015.11.016
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody, Sci Transl Med, vol.6, issue.230, pp.230-275, 2014. ,
,
, Med Clin (Barc), vol.145, pp.264-272, 2015.
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors, J Clin Endocrinol Metab, vol.98, issue.4, pp.1361-75, 2013. ,
Endocrinological side-effects of immune checkpoint inhibitors, Curr Opin Oncol, vol.28, issue.4, pp.278-87, 2016. ,
Incidence of ThyroidRelated Adverse Events in Melanoma Patients Treated With Pembrolizumab, J Clin Endocrinol Metab, vol.101, issue.11, pp.4431-4440, 2016. ,
Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism, Am J Emerg Med, 2017. ,
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis, JAMA Oncol, 2017. ,
, Good pharmacovigilance practices)-Mise à jour prenant en compte l'arrêté du 10 juin 2011 relatif aux modalités de signalement des effets indésirables par les patients et les associations agréées de patients, Bonnes pratiques de pharmacovigilance
, OPDIVO-EPAR summary of product characteristics, 2017.
, KEYTRUDA-EPAR summary of product characteristics, 2017.
, YERVOY-EPAR summary of product characteristics, 2017.
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr Relat Cancer, vol.21, issue.2, pp.371-81, 2014. ,
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann Oncol, vol.28, issue.3, pp.583-589, 2017. ,
DOI : 10.1093/annonc/mdw640
URL : https://academic.oup.com/annonc/article-pdf/28/3/583/24169269/mdw640.pdf
Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists, Cancer Med ,
DOI : 10.1002/cam4.1145
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1145
,
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy, Eur J Endocrinol, vol.164, issue.2, pp.303-310, 2011. ,
DOI : 10.1530/eje-10-0833
URL : https://eje.bioscientifica.com/downloadpdf/journals/eje/164/2/303.pdf
Subclinical hypothyroidism, N Engl J Med, vol.345, issue.4, pp.260-265, 2001. ,
DOI : 10.4103/0973-0354.106807